GlaxoSmithKline (GSK) confirmed it is reviewing roles at its Barnard Castle site as part of operational cuts over a three-year period.
Helen has expressed her sincere disappointment that valued jobs in her constituency are being put at risk.
Helen said: “GSK has committed to a long-term future in Barnard Castle, and are building new production facilities to be ready in the next few years. These job losses are part of a cost-cutting exercise and very disappointing.
“By coincidence last week the Business, Energy and Industrial Strategy (BEIS) select committee published a report on Brexit and pharmaceuticals. A few months ago the chairman of GSK told me that Brexit would add £50million to their costs.
“This is a clear argument of why the UK must commit to staying in the customs union and European Medicines Agency to strengthen our position in the UK and protect jobs.”